tradingkey.logo
搜尋

Myriad Genetics Inc

MYGN
添加自選
4.140USD
+0.130+3.24%
收盤 09-24 16:00(美東)
391.02M總市值
虧損本益比TTM

關於 Myriad Genetics Inc 公司

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Myriad Genetics Inc 簡介

公司代碼MYGN
公司名稱Myriad Genetics Inc
上市日期Oct 06, 1995
CEORaha (Samraat S)
員工數量2700
證券類型Ordinary Share
年結日Oct 06
公司地址322 North 2200 West
城市SALT LAKE CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編84116
電話18015843600
網址https://myriad.com/
公司代碼MYGN
上市日期Oct 06, 1995
CEORaha (Samraat S)

Myriad Genetics Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
191.84K
+31.12%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
171.89K
+26.01%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer
Chief Operating Officer
296.53K
-58.32%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
267.80K
+58.57%
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--
Mr. Raj Jampa
Mr. Raj Jampa
Chief Technology Officer
Chief Technology Officer
251.89K
--

常見問題

Myriad Genetics Inc的前五大股東是誰?

Myriad Genetics Inc的前五大股東如下:Mr. Mark S. Verratti

有多少機構持有Myriad Genetics Inc(MYGN)的股份?

截至2026Q1,共有539家機構持有Myriad Genetics Inc的股份,合計持有的股份價值約為102.95M,占公司總股份的109.00% 。與2025Q4相比,機構持股有所增加,增幅為-7290509.00。

哪個業務部門對Myriad Genetics Inc的收入貢獻最大?

在2026Q1,Hereditary Cancer業務部門對Myriad Genetics Inc的收入貢獻最大,創收114.10M,占總收入的59.83% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有